Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) EBITDA: 2009-2024

Historic EBITDA for Fortress Biotech (FBIO) over the last 16 years, with Dec 2024 value amounting to -$110.4 million.

  • Fortress Biotech's EBITDA rose 69.17% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.4 million, marking a year-over-year increase of 15.68%. This contributed to the annual value of -$110.4 million for FY2024, which is 22.46% up from last year.
  • Fortress Biotech's EBITDA amounted to -$110.4 million in FY2024, which was up 22.46% from -$142.3 million recorded in FY2023.
  • Fortress Biotech's 5-year EBITDA high stood at -$94.3 million for FY2020, and its period low was -$203.6 million during FY2022.
  • Moreover, its 3-year median value for EBITDA was -$142.3 million (2023), whereas its average is -$152.1 million.
  • In the last 5 years, Fortress Biotech's EBITDA slumped by 100.00% in 2021 and then skyrocketed by 30.08% in 2023.
  • Over the past 5 years, Fortress Biotech's EBITDA (Yearly) stood at -$94.3 million in 2020, then plummeted by 100.00% to -$188.5 million in 2021, then dropped by 7.97% to -$203.6 million in 2022, then surged by 30.08% to -$142.3 million in 2023, then grew by 22.46% to -$110.4 million in 2024.